Beam Therapeutics Stock Analysis

Beam Stock Analysis Notes

About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Beam Therapeutics was currently reported as 9.97. The company recorded a loss per share of 1.58. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people. For more info on Beam Therapeutics please contact John MBA at 857 327 8775 or go to https://beamtx.com.

Beam Therapeutics Investment Alerts

Beam Therapeutics Upcoming and Recent Events

Beam Largest EPS Surprises

View All Earnings Estimates

Beam Therapeutics Environmental, Social, and Governance (ESG) Scores

Beam Stock Institutional Investors

Note, although Beam Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Beam Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.94 B.

Beam Profitablity

The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.46.

Management Efficiency

Beam Therapeutics has return on total asset (ROA) of (0.0928) % which means that it has lost $0.0928 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1829) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to drop to -0.09. In addition to that, Return On Capital Employed is likely to grow to -0.15. At this time, Beam Therapeutics' Asset Turnover is very stable compared to the past year.

Technical Drivers

As of the 18th of January 2025, Beam Therapeutics shows the risk adjusted performance of (0.01), and Mean Deviation of 3.55. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Beam Therapeutics information ratio, and the relationship between the coefficient of variation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 23.44 per share. Given that Beam Therapeutics has information ratio of (0.02), we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Beam Therapeutics Price Movement Analysis

Beam Therapeutics Insider Trading Activities

Beam Therapeutics Outstanding Bonds

Beam Therapeutics Predictive Daily Indicators

Beam Therapeutics Corporate Filings

Beam Therapeutics Forecast Models

Beam Therapeutics' time-series forecasting models are one of many Beam Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Beam Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Beam Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Beam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Beam Therapeutics. By using and applying Beam Stock analysis, traders can create a robust methodology for identifying Beam entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Beam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Beam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Beam Therapeutics stock analysis indicators help investors evaluate how Beam Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Beam Therapeutics shares will generate the highest return on investment. By understating and applying Beam Therapeutics stock analysis, traders can identify Beam Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.